- Immunovant Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Immunovant Inc To Discuss Portfolio Update Call TranscriptNov 28, 2023
- Immunovant Inc Initial Phase 1 Results Call TranscriptSep 26, 2023
- Immunovant Inc Fireside Chat Hosted by LifeSci Capital TranscriptDec 08, 2022
- Immunovant Inc Investor Day TranscriptSep 28, 2022
- Immunovant Inc To Discuss On Two New Indications For Batoclimab Call TranscriptSep 07, 2022
- Q4 2022 Immunovant Inc Earnings Call TranscriptJun 08, 2022$3.92 (-8.20%)Earnings
- Immunovant Inc at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Immunovant Inc To Host R&D Day (Virtual) TranscriptMar 30, 2022
- Immunovant Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call TranscriptJan 05, 2022
- Immunovant Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Immunovant Inc at Roivant R&D Day (Virtual) TranscriptSep 28, 2021
- Q1 2022 Immunovant Inc Earnings Call TranscriptAug 09, 2021$7.78 (+0.39%)Earnings
- Q4 2021 Immunovant Inc Earnings Call TranscriptJun 01, 2021$9.4 (-37.99%)Earnings
- Immunovant, Inc. - Special Call TranscriptFeb 02, 2021
- Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Immunovant, Inc. - Special Call TranscriptAug 25, 2020
- Immunovant Inc Annual Shareholders Meeting TranscriptAug 19, 2020
- Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update TranscriptMar 30, 2020
Immunovant Inc at Roivant R&D Day (Virtual) Transcript
Thanks, Paul. Appreciate the introduction. Thank you, Robyn, for joining me today.
Thank you. Thank you, Pete.
I'm going to start out with a brief overview of our market and our assets, and then we'll get into our Q&A. I'll be making some forward-looking statements, and I direct investors to this slide on our website.
So our vision -- we're in immunology and our vision is really to make a big, big difference for patients. We want to bring therapies to market that improve substantially on the standard of care. That's what our vision guides us towards. Our asset is a fully human monoclonal antibody targeting FcRn. And by targeting and blocking the Fc receptor, we lower free floating IgG. Now I'm not showing data today in the interest of time, but the IgG reductions that we reported are among the deepest of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)